Takeda Pharmaceutical (TAK) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $0.23
- EPS estimate
- $0.17
- EPS surprise
- +33.21%
- Revenue surprise
- +7.83%
- Revenue
- $7.7B
- Revenue estimate
- $7.1B
- Reported
- Jul 30, 2026
Takeda reported fiscal Q1 2027 results on July 30, 2026, for the quarter ended June 30, 2026. Earnings per share were $0.23, ahead of the $0.17 estimate by 33.21%. Revenue of $7.7 billion beat the $7.1 billion consensus by 7.83%. Against Q1 2026, EPS fell about 12% from $0.26, while revenue rose from $7.4 billion. The quarter followed a loss of $0.05 per share in fiscal Q4 2026.
Results swing widely. Takeda posted a loss in seven of the last 20 quarters, including four of the last five fiscal Q4s, with the deepest at $0.23 per share in Q4 2025. Annual EPS was $0.74 in fiscal 2023, $0.32 in 2024, $0.21 in 2025 and $0.39 in 2026. Quarterly revenue stayed between $6.7 billion and $8.4 billion. Takeda topped the EPS estimate in 12 of the 20 quarters, and several misses look large in percentage terms because the estimates were close to zero.
Takeda reported fiscal Q2 between October 26 and October 31 in each of the last four years. That points to late October 2026 for the next report. It will show whether the profit in Q1 2027 carries into the second quarter of the fiscal year.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Jul 30, 2026 | $0.17 | $0.23 | +33.21% | $7.7B | SEC |
| Q4 2026 | May 13, 2026 | −$0.08 | −$0.05 | +34.75% | $6.9B | SEC |
| Q3 2026 | Jan 29, 2026 | $0.14 | $0.21 | +56.23% | $7.7B | SEC |
| Q2 2026 | Oct 30, 2025 | $0.07 | −$0.03 | −136.29% | $7.2B | SEC |
| Q1 2026 | Jul 30, 2025 | $0.17 | $0.26 | +54.90% | $7.4B | SEC |
| Q4 2025 | May 8, 2025 | −$0.03 | −$0.23 | −718.71% | $7.3B | SEC |
| Q3 2025 | Jan 30, 2025 | $0.09 | $0.05 | −42.67% | $7.4B | SEC |
| Q2 2025 | Oct 31, 2024 | $0.12 | $0.19 | +53.96% | $7.7B | SEC |
| Q1 2025 | Jul 31, 2024 | $0.12 | $0.20 | +65.47% | $8.0B | SEC |
| Q4 2024 | May 9, 2024 | $0.00 | −$0.01 | −339.29% | $6.7B | SEC |
| Q3 2024 | Feb 2, 2024 | $0.10 | $0.23 | +132.55% | $7.5B | SEC |
| Q2 2024 | Oct 26, 2023 | $0.10 | −$0.10 | −207.36% | $7.0B | SEC |
| Q1 2024 | Jul 27, 2023 | $0.14 | $0.20 | +44.50% | $7.5B | SEC |
| Q4 2023 | May 11, 2023 | $0.05 | $0.07 | +46.53% | $7.1B | SEC |
| Q3 2023 | Feb 2, 2023 | $0.28 | $0.29 | +3.14% | $8.4B | SEC |
| Q2 2023 | Oct 27, 2022 | $0.13 | $0.13 | +0.67% | $6.8B | — |
| Q1 2023 | Jul 28, 2022 | $0.24 | $0.25 | +7.03% | $7.3B | — |
| Q4 2022 | May 11, 2022 | $0.06 | −$0.03 | −144.72% | $6.8B | — |
| Q3 2022 | Feb 3, 2022 | $0.22 | $0.16 | −27.21% | $7.8B | — |
| Q2 2022 | Invalid Date | $0.23 | −$0.05 | −120.52% | $7.4B | — |
Quarterly revenue
Frequently asked questions
When did Takeda Pharmaceutical (TAK) last report earnings?
Takeda Pharmaceutical last reported on Jul 30, 2026, covering fiscal Q1 2027.
Did TAK beat earnings estimates?
Yes. Takeda Pharmaceutical reported EPS of $0.23 for Q1 2027 against a $0.17 estimate — a 33.21% beat.
How much revenue did TAK report last quarter?
Takeda Pharmaceutical reported $7.7B in revenue for Q1 2027, against a consensus estimate of $7.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.